Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338949 · ClinicalTrials.gov registry record · Phase 4
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
A Phase 4 study of Schizophrenia and Insulin Resistance, sponsored by Veterans Medical Research Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT00338949 is a Phase 4 study of Schizophrenia and Insulin Resistance that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 77 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00338949, a Phase 4 study of Schizophrenia and Insulin Resistance, has completed, sponsored by Veterans Medical Research Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.
Conditions Studied
Interventions
- DRUG Switch
- DRUG Control
Study Locations (1)
California
- VA San Diego Healthcare System - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338949
The ClinicalTrials.gov registry entry for NCT00338949 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The listed sponsor is Veterans Medical Research Foundation, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Switch is the first listed.
NCT00338949 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00338949 about?
NCT00338949 is a clinical study titled "Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes". This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.
What is the current status of trial NCT00338949?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2006-06. Estimated completion is 2009-12.
What conditions does trial NCT00338949 study?
This clinical trial studies the following conditions: Schizophrenia, Insulin Resistance, Metabolic Syndrome X.
What interventions are being tested in trial NCT00338949?
The interventions under investigation include: Switch (DRUG), Control (DRUG).
Who is sponsoring clinical trial NCT00338949?
This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00338949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.